Search Within

Gregory J Riely

  1. "Matthew Hellmann"
Formats
  1. Journal Article (34)
  2. Meeting Abstract (13)
  3. Correspondence (1)
  4. Research Letter (1)
Groups
  1. Department of Medicine (49)
  2. Solid Tumor Oncology Division (49)
  3. Thoracic Oncology (49)
  4. Hematology-Oncology Fellows (40)
  5. GSK Faculty (39)
  6. Weinberg Fellows (39)

More Groups

People
  1. Matthew Hellmann (49)
  2. Mark Kris (33)
  3. Marc Ladanyi (31)
  4. Charles Rudin (30)
  5. Hira Rizvi (25)
  6. Maria Arcila (22)

More People

Years
  1. 2024 (1)
  2. 2023 (3)
  3. 2022 (5)
  4. 2021 (4)
  5. 2020 (5)
  6. 2019 (10)

More Years

Publications
  1. Journal of Clinical Oncology (13)
  2. Annals of Oncology (8)
  3. Clinical Cancer Research (7)
  4. Journal of Thoracic Oncology (5)
  5. JCO Precision Oncology (3)
  6. Cancer Discovery (2)

More Publications

Publishers
  1. American Society of Clinical Oncology (16)
  2. Oxford University Press (10)
  3. American Association for Cancer Research (9)
  4. Elsevier Inc. (5)
  5. Nature Publishing Group (4)
  6. Biomed Central Ltd (1)

More Publishers

Results (49)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Intratumoral escherichia is associated with improved survival to single-agent immune checkpoint inhibition in patients with advanced non–small-cell lung cancer
    Journal Article

    Elkrief, A.; Montesion, M.; Sivakumar, S.; Hale, C.; Bowman, A. S.; Begüm Bektaş, A.; Bradic, M.; Kang, W.; Chan, E.; Gogia, P.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Outcomes of combination platinum-doublet chemotherapy and anti-PD(L)-1 blockade in KRAS(G12C) mutant non-small cell lung cancer
    Journal Article

    Elkrief, A.; Riccuiti, B.; Alessi, J. V.; Fei, T.; Kalvin, H. L.; Egger, J. V.; Rizvi, H.; Thummalapalli, R.; Lamberti, G.; Plodkowski, A.; more...
    The Oncologist (2023)

    Fulltext@MSK | Save
  • Clinical and molecular features of long-term response to immune checkpoint inhibitors in patients with advanced non–small cell lung cancer
    Journal Article

    Thummalapalli, R.; Ricciuti, B.; Bandlamudi, C.; Muldoon, D.; Rizvi, H.; Elkrief, A.; Luo, J.; Alessi, J. V.; Pecci, F.; Lamberti, G.; more...
    Clinical Cancer Research (2023)

    Fulltext@MSK | Save
  • Efficacy of PD-(L)1 blockade monotherapy compared with PD-(L)1 blockade plus chemotherapy in first-line PD-L1-positive advanced lung adenocarcinomas: A cohort study
    Journal Article

    Elkrief, A.; Alessi, J. M. V.; Ricciuti, B.; Brown, S.; Rizvi, H.; Preeshagul, I. R.; Wang, X.; Pecci, F.; Di Federico, A.; Lamberti, G.; more...
    Journal for ImmunoTherapy of Cancer (2023)

    Fulltext@MSK | Save
  • Impact of intratumoral microbiome on immunotherapy treatment outcomes in patients with advanced non-small cell lung cancer
    Meeting Abstract

    Elkrief, A.; Bowman, A.; Rizvi, H.; Hellmann, M.; Riely, G. J.; Schoenfeld, A. J.; Ladanyi, M.; Vanderbilt, C. M.
    Annals of Oncology (2022)

    Fulltext@MSK | Save
  • Outcomes of single-agent PD-(L)-1 versus combination with chemotherapy in patients with PD-L1-high (≥ 50%) lung cancer
    Meeting Abstract

    Elkrief, A.; Machado Alessi, J. V.; Ricciuti, B.; Rizvi, H.; Preeshagul, I. R.; Egger, J. V.; Chaft, J. E.; Rudin, C. M.; Riely, G. J.; Kris, M. G.; more...
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • Overall survival with circulating tumor DNA-guided therapy in advanced non-small-cell lung cancer
    Journal Article

    Jee, J.; Lebow, E. S.; Yeh, R.; Das, J. P.; Namakydoust, A.; Paik, P. K.; Chaft, J. E.; Jayakumaran, G.; Brannon, A. R.; Benayed, R.; more...
    Nature Medicine (2022)

    Fulltext@MSK | Save
  • Systemic and oligo-acquired resistance to PD-(L)1 blockade in lung cancer
    Journal Article

    Schoenfeld, A. J.; Rizvi, H. A.; Memon, D.; Shaverdian, N.; Bott, M. J.; Sauter, J. L.; Tsai, C. J.; Lihm, J.; Hoyos, D.; Plodkowski, A. J.; more...
    Clinical Cancer Research (2022)

    Fulltext@MSK | Save
  • Immune biomarkers and response to checkpoint inhibition of BRAF(V600) and BRAF non-V600 altered lung cancers
    Journal Article

    Murciano-Goroff, Y. R.; Pak, T.; Mondaca, S.; Flynn, J. R.; Montecalvo, J.; Rekhtman, N.; Halpenny, D.; Plodkowski, A. J.; Wu, S. L.; Kris, M. G.; more...
    British Journal of Cancer (2022)

    Fulltext@MSK | Save
  • Chemo-immunotherapy outcomes of KRAS-G12C mutant lung cancer compared to other molecular subtypes of KRAS-mutant lung cancer
    Meeting Abstract

    Arbour, K. C.; Ricciuti, B.; Rizvi, H.; Hellmann, M. D.; Yu, H. A.; Ladanyi, M.; Kris, M. G.; Arcila, M. E.; Rudin, C. M.; Lito, P.; more...
    Journal of Clinical Oncology (2021)

    Fulltext@MSK | Save